User profiles for CARMELO CARLO-STELLA
Carmelo Carlo-StellaHumanitas University and IRCCS Humanitas Research Hospital Verified email at hunimed.eu Cited by 15525 |
Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli
CD2 + T lymphocytes obtained from either the donor of bone marrow stromal cells (BMSCs)
or a third party were cultured in mixed lymphocyte reactions (MLRs) with either allogeneic …
or a third party were cultured in mixed lymphocyte reactions (MLRs) with either allogeneic …
[HTML][HTML] Glofitamab for relapsed or refractory diffuse large B-cell lymphoma
MJ Dickinson, C Carlo-Stella… - … England Journal of …, 2022 - Mass Medical Soc
Background The prognosis for patients with relapsed or refractory diffuse large B-cell lymphoma
(DLBCL) is poor. Glofitamab is a bispecific antibody that recruits T cells to tumor cells. …
(DLBCL) is poor. Glofitamab is a bispecific antibody that recruits T cells to tumor cells. …
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
…, S He, Y Qin, D Ungar, X Zhang, C Carlo-Stella - The Lancet …, 2021 - thelancet.com
Background Patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who
do not respond to or who have progressive disease after salvage therapies have a poor …
do not respond to or who have progressive disease after salvage therapies have a poor …
[HTML][HTML] Glofitamab, a novel, bivalent CD20-targeting T-cell–engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell …
…, G Iacoboni, C Carlo-Stella… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE Glofitamab is a T-cell–engaging bispecific antibody possessing a novel 2: 1
structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. This phase I …
structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. This phase I …
[PDF][PDF] Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy
…, R Schiavo, P Pedrazzoli, C Carlo-Stella - Journal of Clinical …, 2000 - Citeseer
Purpose: To review recent advances in peripheralblood progenitor-cell (PBPC)
transplantation in order to define the optimal cell dose required for autologous and allogeneic …
transplantation in order to define the optimal cell dose required for autologous and allogeneic …
Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells
…, J Brody, G Inghirami, C Carlo-Stella… - Blood, The Journal …, 2015 - ashpublications.org
Classical Hodgkin lymphoma (cHL) is characterized by sparsely distributed Hodgkin and
Reed-Sternberg (HRS) cells amid reactive host background, complicating the acquisition of …
Reed-Sternberg (HRS) cells amid reactive host background, complicating the acquisition of …
Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma
…, G Gaidano, S Hohaus, C Carlo-Stella… - Blood, The Journal …, 2018 - ashpublications.org
The rarity of neoplastic cells in the biopsy imposes major technical hurdles that have so far
limited genomic studies in classical Hodgkin lymphoma (cHL). By using a highly sensitive …
limited genomic studies in classical Hodgkin lymphoma (cHL). By using a highly sensitive …
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma
Anti–programmed cell death protein 1 (PD-1) monoclonal antibodies are being increasingly
tested in patients with advanced lymphoma. Following treatment, many of those patients are …
tested in patients with advanced lymphoma. Following treatment, many of those patients are …
Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen)
Mantle cell lymphoma (MCL) is rarely cured with standard-dose chemotherapy. From January
1997 to February 2000, 28 previously untreated advanced-stage MCL patients younger …
1997 to February 2000, 28 previously untreated advanced-stage MCL patients younger …
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma
The prognosis for patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL)
remains poor, with a need for alternatives to current salvage therapies. …
remains poor, with a need for alternatives to current salvage therapies. …